Total
0
Shares
BARD1 Life Sciences (ASX:BD1) - CEO, Leearne Hinch
CEO, Leearne Hinch
Source: BARD1 Life Sciences
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • BARD1 Life Sciences (BD1) appoints Greg Rice as chief scientific officer (CSO) to fast-track development of its cancer diagnostic tests
  • Dr Rice has more than 30 years’ experience across oncology, perinatology, exosome-based research and clinical translational research
  • He will lead BD1’s R&D programs with a focus on advancing its tests for breast and ovarian cancers towards clinical and commercial milestones
  • Former CSO Peter French will transition to a new position as the company’s strategic technology advisor
  • Shares are down 0.38 per cent at $1.31 at 12:52 pm AEST

BARD1 Life Sciences (BD1) has appointed medical researcher Greg Rice to the role of chief scientific officer (CSO) to fast-track development its diagnostic tests.

Dr Rice will join the company on September 20 and lead the company’s research and development (R&D) programs.

The internationally recognised scientist has more than 30 years’ expertise in oncology, perinatology, exosome-based research and clinical translational research, and has published more than 280 peer-reviewed publications.

Specifically, he will focus on advancing the company’s SubB2M tests for breast and ovarian cancers towards clinical and commercial milestones, while building BD1’s next generation exosome-based diagnostic pipeline and supporting its BARD1 and hTERT programs.

The company’s CEO Leearne Hinch said she was pleased to appoint someone of Dr Rice’s calibre to lead BD1’s R&D programs into clinical development and commercialisation.

“Greg is a data-driven and commercially focused scientist with a track record in cancer diagnostics and is strongly motivated to deliver clinically important diagnostics to improve patient outcomes and save lives,” Dr Hinch said.

The incoming CSO said he was delighted to join BD1.

“My translational research interests and career focus have been on oncology, diagnostics, women’s health, and exosome-based technologies, which are strongly aligned with BARD1’s diagnostic portfolio and commitment to improving patient health outcomes,” Dr Rice said.

“My goals are to ensure the timely delivery of clinically relevant products, achievement of key clinical milestones and regulatory approvals initially in the US and Europe.”

Meanwhile, BARD1’s former CSO Peter French is set to transition to a new role as the company’s strategic technology advisor and will continue to support the R&D programs.

Shares were down 0.38 per cent at $1.31 at 12:52 pm AEST.

BD1 by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.